Elizabeth Holmes, the founder of embattled biotech Theranos, and former company president Sunny Balwani have been charged with massive fraud by the U.S. Securities and Exchange Commission. Source: BioSpace

On April 23, the FDA’s arthritis advisory committee will take another look at Eli Lilly's re-submission for their moderate-to-severe rheumatoid arthritis drug. Source: BioSpace

IDEAYA Biosciences has raised $94 million in Series B funding to drive multiple clinical studies in 2019. Source: BioSpace

The Wall Street Journal speculated today that it won't be long before drug manufacturers start consolidating in order to improve their bottom lines. Source: BioSpace

Celgene has a deep pipeline and a $69 billion market cap, but it could consider going private in 2019 via a leveraged buyout. Source: BioSpace

A U.S. Food and Drug Administration announced their decision to slap a clinical hold on Solid Biosciences Inc.’s experimental gene therapy treatment for Duchenne muscular dystrophy. Source: BioSpace

Ionis Pharmaceuticals has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion. Source: BioSpace

Foghorn Therapeutics has officially launched with a $50 million investment and the ambitious goal of altering the way our genes work. Source: BioSpace

Auris Medical has gone down swinging again in attempting to develop a treatment for tinnitus after it announced its Phase III trial failed to meet endpoints. Source: BioSpace

PharmaJet released positive interim results from the U.S. Army’s Phase I clinical trial of two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS). Source: BioSpace